In view of the profound impact of HFpEF on myositis disease activity and overall survival, it was of critical significance to reinforce the awareness of screening and management of HFpEF in IIM, especially in patients with AMA-M2 and anti-SRP antibody. Here, UCN2 is linked to myositis disease.